Changes in the intestinal absorption mechanism of icariin in the nanocavities of cyclodextrins

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4239-4249

  Zhang, Ye ^a   Wang, Qiang Song ^a   Cui, Yuan Lu ^a   Meng, Fan Cui ^b   Lin, Ke Ming ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Cyclodextrin; Icariin; Inclusion complex; Intestinal absorption; Molecular modeling; P glycoprotein (Pgp)

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ADENOSINE TRIPHOSPHATASE; BETA CYCLODEXTRIN; ICARIIN; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANISOTROPY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; EMISSION ANISOTROPY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; INFRARED SPECTROSCOPY; INTESTINE ABSORPTION; INTESTINE PERFUSION; MALE; MOLECULAR MODEL; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ULTRAVIOLET SPECTROSCOPY; X RAY POWDER DIFFRACTION;

ANALYSIS OF VARIANCE; ANIMALS; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG INTERACTIONS; FLAVONOIDS; INTESTINAL ABSORPTION; MALE; MODELS, MOLECULAR; NANOSTRUCTURES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTRUM ANALYSIS;

RATTUS;

EID: 84870307351     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33014     Document Type: Article

References (47)

1. Frew SE, Sammut SM, Shore AF, etal. Chinese health biotech and the billion-patient market. Nature Biotechnol. 2008;26(1):37-53.
2. Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res. 2007;22(7):1072-1079.
3. Makarova MN, Pozharitskaya ON, Shikov AN, Tesakova SV, Makarov VG, Tikhonov VP. Effect of lipid-based suspension of Epimedium koreanum Nakai extract on sexual behavior in rats. J Ethnopharmacol. 2007;114(3):412-416.
4. Meng FH, Li YB, Xiong ZL, Jiang ZM, Li FM. Osteoblastic proliferative activity of Epimedium brevicornum Maxim. Phytomedicine. 2005; 12(3):189-193.
5. Pan Y, Zhang WY, Xia X, Kong LD. Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol Pharm Bull. 2006;29(12):2399-2403.
6. Pan Y, Kong L, Xia X, Zhang W, Xia Z, Jiang F. Antidepressant-like effect of icariin and its possible mechanism in mice. Pharmacol Biochem Behav. 2005;82(4):686-694.
7. Huang X, Zhu D, Lou Y. A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol. 2007;564(1-3):26-36.
8. Mo SF, Zhou F, Lv YZ, Hu QH, Zhang DM, Kong LD. Hypouricemic action of selected flavonoids in mice: structure-activity relationships. Biol Pharm Bull. 2007;30(8):1551-1556.
9. Li F, Gong QH, Wu Q, Lu YF, Shi JS. Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol Biochem Behav. 2010;96(3):301-305.
10. Xin ZC, Kim EK, Lin CS, etal. Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003; 5(1):15-18.
11. Zhang YP, Xu W, Li N, etal. LC-MS-MS method for simultaneous determination of icariin and its active metabolite icariside II in human plasma. Chromatographia. 2008;68(3-4):245-250.
12. Xu W, Zhang Y, Yang M, etal. LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma. J Pharm Biomed Anal. 2007;45(4):667-672.
13. Cheng S, Qiu F, Wang S, He J. HPLC analysis and pharmacokinetics of icariin in rats. J Sep Sci. 2007;30(9):1307-1312.
14. Chao J, Wang H, Zhao W, Zhang M, Zhang L. Investigation of the inclusion behavior of chlorogenic acid with hydroxypropyl-β-cyclodextrin. Int J Biol Macromol. 2012;50(1):277-282.
15. Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005;302(1-2):18-28.
16. Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85(11):1142-1169.
17. Li J, Xiao H, Li J, Zhong Y. Drug carrier systems based on water-soluble cationic beta-cyclodextrin polymers. Int J Pharm. 2004;278(2): 329-342.
18. Liu J, Qiu L, Gao J, Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. Int J Pharm. 2006;312(1-2):137-143.
19. Kano K, Kitagishi H, Tanaka S. Characterization of an inclusion complex of 5,10,15,20-tetrakis(4-sulfonatophenyl)-porphinato iron and an O-methylated β-cyclodextrin dimer having a pyridine linker and its related complexes in aqueous solution. J Incl Phenom Macrocycl Chem. 2006;56(1-2):69-74.
20. Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005; 43(10):1451-1459.
21. Castronuovo G, Niccoli M. Thermodynamics of inclusion complexes of natural and modified cyclodextrins with propranolol in aqueous solution at 298 K. Bioorg Med Chem. 2006;14(11):3883-3887.
22. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm Sci Tech. 2005;6(2):E329-E357.
23. Brewster ME, Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie. 2002;57(2):94-101.
24. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3(12):1023-1035.
25. Duchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J Control Release. 1999;62(1-2):263-268.
26. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86(2): 147-162.
27. Arima H, Yunomae K, Hirayama F, Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther. 2001;297(2):547-555.
28. Meyer dos Santos S, Weber CC, Franke C, Muller WE, Eckert GP. Cholesterol: Coupling between membrane microenvironment and ABC transporter activity. Biochem Biophys Res Commun. 2007;354(1): 216-221.
29. Fenyvesi F, Fenyvesi E, Szente L, etal. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci. 2008;34(4-5): 236-242.
30. Cai C, Zhu H, Chen J. Overexpression of caveolin-1increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochem Biophys Res Commun. 2004;320(3):868-874.
31. Calabro ML, Tommasini S, Donato P, etal. The rutin/beta-cyclodextrin interactions in fully aqueous solution: spectroscopic studies and biological assays. J Pharm Biomed Anal. 2005;36(5):1019-1027.
32. Kunes M, Svoboda Z, Kvetina J, Herout V, Herink J, Bajgar J. Intestinal single-pass in situ perfusion technique in rat: the influence of L-carnitine on absorption of 7-methoxytacrine. Biomed Pap Med Fac Univ Palacky, Olomouc Czech Repub. 2005;149(2):433-435.
33. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur J Pharm Biopharm. 2009;71(2):310-317.
34. Belli S, Elsener PM, Wunderli-Allenspach H, Kramer SD. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities. J Pharm Sci. 2009;98(5): 1905-1918.
35. Higuchi T, Connors K. Phase solubility techniques. Advances in Analytical Chemistry and Instrumentation. 1965;7:117-212.
36. Yang H, Parniak MA, Isaacs CE, Hillier SL, Rohan LC. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J. 2008;10(4): 606-613.
37. Badr-Eldin SM, Elkheshen SA, Ghorab MM. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation. Eur J Pharm Biopharm. 2008; 70(3):819-827.
38. Cappello B, Di Maio C, Iervolino M, Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-beta-cyclodextrin. J Incl Phenom Macrocycl Chem. 2006;54(3-4):289-294.
39. Schneider HJ, Hacket F, Rudiger V, Ikeda H. NMR studies of cyclodextrins and cyclodextrin complexes. Chem Rev. 1998;98(5):1755-1786.
40. de Araujo MV, Vieira EK, Silva Lazaro G, etal. Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008;16(10):5788-5794.
41. Jullian C, Orosteguis T, Perez-Cruz F, Sanchez P, Mendizabal F, Olea-Azar C. Complexation of morin with three kinds of cyclodextrin. A thermodynamic and reactivity study. Spectrochim Acta A Mol Biomol Spectrosc. 2008;71(1):269-275.
42. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol. 2001;53(7):1007-1013.
43. Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109(7):2989-3011.
44. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. 2004;36(1):57-104.
45. Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco. 2002;57(5): 385-415.
46. Dai F, Liu W. Enhanced gene transfection and serum stability of polyplexes by PDMAEMA-polysulfobetaine diblock copolymers. Biomaterials. 2011;32(2):628-638.
47. Collnot EM, Baldes C, Wempe MF, etal. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm. 2007;4(3): 465-474.